Form 4: Ionis Pharmaceuticals Director Sells Shares

Allene M. Diaz, a Director at Ionis Pharmaceuticals Inc., has sold 10,111 shares of common stock, a transaction executed under a pre-arranged trading plan.

Summary

• Allene M. Diaz, a Director at Ionis Pharmaceuticals Inc. (IONS), reported a sale of 10,111 shares of common stock on July 7, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on November 25, 2025.
• The shares were sold at a weighted average price of $85.4156, with individual sale prices ranging from $85.040 to $85.730.
• Following the sale, Diaz beneficially owns 3,811 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was conducted under a pre-established trading plan, indicating it was likely pre-scheduled and not a reaction to new, non-public information.

Negatives

• Director Allene M. Diaz sold a significant number of shares (10,111) of Ionis Pharmaceuticals Inc. common stock.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling, particularly when executed under a Rule 10b5-1 plan, is a common occurrence and often reflects pre-planned diversification or liquidity needs rather than a negative outlook on the company's future. However, significant sales by directors can sometimes be interpreted by the market as a signal, depending on the volume and context.

Stakeholder Impact

• Shareholders may note the sale by a director, but the use of a Rule 10b5-1 plan suggests it was a planned event and not necessarily a reflection of negative sentiment towards the company's prospects.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, SEC Filing, Insider Trading, Stock Sale, Director Sale, Rule 10b5-1, Beneficial Ownership